NanoViricides, Inc. is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. Utilizing nanoscale materials and processes licensed from TheraCour Pharma, Inc., we are developing anti-viral drugs against a wide range range of human and animal viruses.
NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others
NanoViricides to Accelerate Program for Herpecide Drug Development
Dramatic Effects of Nanoviricides for Treating Herpes Simplex Virus Infection Reproduced in Animal Model
NanoViricides’ Anti-Viral Drug Candidates Show Promise in Lethal Animal Model of Herpes Infection
Anti-Herpes Nanoviricides Reduce Extent of Disease and Mortality of HSV-1 Infected Animals
NanoViricides Reports Good Safety Profile of Optimized FluCide Drug Candidate in GLP-Like Toxicology Study
NanoViricides Ships anti-Ebola Broad-Spectrum Drug Candidates for BSL-4 Level Testing
NanoViricides Acquires cGMP-Compliant Manufacturing and R&D Facility from Inno-Haven
NanoViricides’ Injectable FluCide Drug among ‘Top Ten Infectious Diseases Projects to Watch’
USAMRIID Scientists to Evaluate Nanoviricides Anti-Ebola Drug Candidates
NanoViricides CEO to Discuss Ebola Outbreak on Fox Business News
NanoViricides Announces Delivery of FluCide to BASi to Begin Toxicology Studies
NanoViricides Reports Further Progress in Development of Anti-Ebola Drug Program
NanoViricides Announces Restart of Drug Development Program to Combat Ebola
NanoViricides Dedicates New R&D and cGMP Pilot Manufacturing Facility
NanoViricides Presents FluCide Data at 3rd Annual Influenza Research and Development Conference
NanoViricides Receives $5M Investment from Company Director
NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference
NanoViricides Synthesizes Drug Candidates for Testing Infection with MERS Corona Virus
NanoViricides Honored with IAIR Award for Leadership in Nanomedicine
NanoViricides’ President Honored as ‘Researcher of the Year’
Australia and the Philippines Award Fundamental Patents to NanoViricides
NanoViricides’ Modern R&D Lab and cGMP Clinical Production Facility in Shelton Nears Completion
NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement
NanoViricides New R&D Lab and cGMP Clinical Production Facility in Shelton Nearing Completion
NanoViricides Reports Positive Results from FluCide Non-GLP Study
EMA Awards Orphan Drug Designation to NanoViricides’s DengueCide
NanoViricides Renews Evaluation Contract with Dr. Harris’ Lab for DengueCide
NanoViricides Reports FluCide Drug as Safe in Non-GLP Small Animal Toxicology Study
NanoViricides Reports Dr Boniuk as Single Largest Investor in Recent Registered Direct Offering
NanoViricides Seeks Orphan Drug Designation for DengueCide in the European Union
NanoViricides Progressing on Schedule to Build New Clinical Scale cGMP Production Plant
NanoViricides Enters Non-Disclosure Agreement with the Lovelace Respiratory Research Institute
NanoViricides Signs Confidential Agreement with Public Health England for Testing of Different Nanoviricides
NanoViricides Submits Letter of Intent to File DengueCide Orphan Drug Application with the EMA
NanoViricides Files Orphan Drug Application with the FDA for DengueCide
NanoViricides to Discuss its Broad Drug Pipeline at BIO International Convention
NanoViricides’ Oral and Injectable FluCide Drug Candidates May be Effective against Novel H7N9 Strain
NanoViricides to Participate in 15th Annual BIO CEO and Investor Conference
NanoViricides Provides Update on Influenza Program
NanoViricides Retains Id3A as Architect for cGMP Pilot Production Facility
NanoViricides Receives Final Tranche of $2.5M Financing from Seaside
NanoViricides, Bioanalytical Systems Partner for Drug Development Studies
NanoViricides’ Anti-Influenza Drug Candidates Demonstrate Significant Results
Anti-Viral Drug Delivery Platform from Nanoviricides Recognised in Bionanotechnology II
NanoViricides’ CEO to Discuss Company’s Latest Developments at NanoBusiness Conference
NanoViricides Plans cGMP Pilot Plant for Nanoviricides Drug Candidates in Connecticut
NanoViricides Advances its Drug Product Line Through IND Submission
Nanovircides Plans to Use its Optimization Technology to Enhance its HIVCide Candidate
NanoViricides’ Anti-HIV Candidate Protects Human T Cells Similar to HAART Therapy
NanoViricides to Expand Production of Drug Candidates for Toxicological Studies
FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus
Nanoparticles of Drug Candidates Reduce Viral Count in Lungs of Influenza-Infected Animals
NanoViricides to Participate on Nanomedicine Panel at NanoBusiness2010 Conference
Presentation on Study Results of NanoViricides Anti-Ebola Agents
Nanoviricides Reports Significant Efficacy of Anti-Dengue Drug Candidates in Initial Studies
Anti-Dengue Nanoviricides Proved Effective in Preliminary Studies
NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing
NanoViricides Partners with Dr. Rosenthal to Evaluate Nanoviricide Anti-HSV Drug Candidates
NanoViricides CEO Presents Lifetime Data from FluCide at Influenza Congress USA 2009
NanoViricides Completes Number of Financing Activities
NanoViricides CEO to Serve as Panelist at 2nd Annual Livingston Healthcare Summit
NanoViricides President Describes Technology and Pipeline at NanoBusiness 2009 Conference
NanoViricides Announces Drug Candidate Reduces Herpes Simplex Viral Load by 99.99 Percent
Expanded Testing under a Material Transfer Agreement with a Pharma Company
NanoViricides Signs Pre-Clinical Study Agreement for the Evaluation of FluCide
Major Research Institution Approves Investigator-Initiated Study
Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye
Company Focusing on Developing Nanoviricides for Topical Anti-Viral Eye Drug and Anti-HIV Drug
NanoViricides Announces Update on Eye Drug Development
NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs
Renowned Japanese Corneal Researcher to Confirm NanoViricides Ekc-Cide Animal Study Results
Siyu Chen, Ph.D.
In this interview, we discuss a new approach to surface-enhanced Raman spectroscopy that utilizes nano-pockets to capture target molecules, ensuring a highly sensitive way to detect chemical processes.
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
This article outlines how Unity, Oxford Instruments’ new detector for a revolutionary new imaging technique, can be used to revolutionize imaging.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.